Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
PhaseBio Pharmaceuticals, Inc. PHAS
$0.07
На 18:01, 12 мая 2023
+11 328.57%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
4.08
-
week52low
0.04
-
Revenue
10831
-
P/E TTM
0
-
Beta
2.86914600
-
EPS
-2.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мар 2023 г. в 04:00
Описание компании
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 15 авг 2022 г. |
| Needham | Buy | Buy | 28 мар 2022 г. |
| Needham | Buy | Buy | 17 июн 2021 г. |
| Needham | Buy | Buy | 16 мар 2021 г. |
| Citigroup | Buy | Buy | 06 апр 2020 г. |
| William Blair | Market Perform | Outperform | 28 сент 2022 г. |
| Needham | Hold | Buy | 28 сент 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 24 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| NEW ENTERPRISE ASSOCIATES 13 LP | D | 4857525 | 1784109 | 25 окт 2022 г. |
| Burkhardt Glen | D | 0 | 11248 | 23 мая 2022 г. |
| Arnold Susan Elizabeth | A | 41236 | 10917 | 20 мая 2022 г. |
| Sharp John P | A | 65767 | 6026 | 20 мая 2022 г. |
| Birchall Jonathan | A | 20000 | 20000 | 20 мая 2022 г. |
| Hanson Kristopher | A | 8463 | 4831 | 20 мая 2022 г. |
| Mow Jonathan P | A | 132502 | 10918 | 20 мая 2022 г. |
| Burkhardt Glen | A | 11248 | 11248 | 20 мая 2022 г. |
| Humphries William D. | A | 2538 | 2538 | 19 мая 2022 г. |
| Humphries William D. | A | 11842 | 11842 | 19 мая 2022 г. |
Новостная лента
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
24/7 Wall Street
17 окт 2022 г. в 19:41
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
12 авг 2022 г. в 11:17
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?